Watson Receives FDA Approval For Fruit, Cinnamon Flavored Nicotine Gums
Equivalent of GSK's Nicorette Fruit Chill and Cinnamon Surge Coated gums
Watson Laboratories, a subsidiary of Watson's, has received approval from the FDA to market its over-the-counter Nicotine Polacrilex Gum USP, 2mg and 4mg strengths, in the coated fruit and cinnamon flavors.
Nicotine Polacrilex Gum coated fruit and cinnamon flavors are the generic equivalent of GlaxoSmithKline Consumer Healthcare's Nicorette Fruit Chill and Cinnamon Surge Coated gums. These are used as an aid to smoking cessation.
Watson is a generic and specialty branded pharmaceutical company, focused on the development and distribution of pharmaceutical generic and specialty branded products. The company has expertise in Urology, Women's Health and Nephrology/Medical.
Related Insight
Suppliers Directory
Gerteis - Roller Compactor Dry Granulators
Gerteis® is a Swiss manufacturer of advanced high quality roller compactor dry granulators who have set the standard with their unique dry granulation technology. Their understanding of the dry granulation process combined with patented roller compaction systems make Gerteis® the technology leaders in the field of dry granulation.
Suppliers
A-Consult - Professional Regulatory Affairs and Drug Safety Services
A-consult offers professional assistance to the pharmaceutical industry within all areas of Regulatory Affairs and Drug Safety.
Suppliers
Centre for Human Drug Research - Early Phase Drug Development
The Centre for Human Drug Research (CHDR) performs clinical studies of innovative medicines with the concept where the maximum amount of information is extracted in the earliest clinical phase, using innovative and complex techniques as reflected in our publication output.
Suppliers
Synergy Outsourcing - Outsourcing and Insourcing Solutions
Synergy outsourcing is a functional service provider giving the outsourcing industry a unique dual channel approach to outsourcing.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Pre-Packaged Diversity Sets of Compounds for Screening
Published by Enamine
White Papers
Fully Automated Dissolution System
Published by Sotax
White Papers
Automated Testing: A Critical Component
Published by Dr Schleuniger Pharmatron
White Papers
Interview with Dr David Orloff
Published by Medpace
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.